Enrolling by invitationPhase 3NCT07228403

Efficacy and Safety Evaluation of Glepaglutide in Treatment of Short Bowel Syndrome

Studying Short bowel syndrome

Last synced from ClinicalTrials.gov April 1, 2026

ℹ

Clinical trial records are synced from ClinicalTrials.gov through automated extraction.

Report missing data

Key facts

Sponsor: Zealand Pharma
Intervention: Glepaglutide 10 mg(drug)
Enrollment: 35 target
Eligibility: 18 years · All sexes
Timeline: 2025 – 2028

Study locations (16)

Mayo Clinic - PPDS, Rochester, Minnesota, United States
Lied Transplant Center at Nebraska Medical Center, Omaha, Nebraska, United States
Cleveland Clinic-9500 Euclid Ave, Cleveland, Ohio, United States
Vanderbilt University Medical Center-Tennesse-1211 21st Ave S, Nashville, Tennessee, United States
UZ Leuven - PPDS, Leuven, Belgium
LHSC - University Hospital, London, Ontario, Canada
AP-HP - Hôpital Beaujon, Clichy, Hauts-de-Seine, France
Universitätsklinikum Frankfurt, Frankfurt am Main, Hesse, Germany
Universitätsmedizin Rostock, Rostock, Mecklenburg-Vorpommern, Germany
Universitätsklinikum Bonn, Bonn, North Rhine-Westphalia, Germany
Charité - Universitätsmedizin Berlin, Berlin, State of Berlin, Germany
Asklepios Klinik St. Georg, Hamburg, Germany
Szpital Skawina sp. z o.o. im. Stanley Dudricka, Skawina, Lesser Poland Voivodeship, Poland
Samodzielny Publiczny Szpitala Kliniczny im. Prof. Witolda Orlowskiego CMKP, Warsaw, Masovian Voivodeship, Poland
Wojewódzki Szpital Specjalistycznyo im. M. Pirogowa w Lodzi, Lodz, Poland
+1 more locations on ClinicalTrials.gov

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Open NCT07228403 on ClinicalTrials.gov

Other trials for Short bowel syndrome

Additional recruiting or active studies for the same condition.

See all trials for Short bowel syndrome →

← Back to all trials